

Telithromycin, the First FDA Approved Ketolide: Just Another Antibiotic?

By Oanh H. Dang, Pharm.D.

References

1. Nuermberger EL, Bishai WR. Antibiotic resistance in *Streptococcus pneumoniae*: what does the future hold? *Clin Infect Dis* 2004;38 Suppl 4:S363-71.
2. Ackermann G, Rodloff AC. Drugs of the 21st century: telithromycin (HMR 3647)—the first ketolide. *J Antimicrob Chemother* 2003;51(3):497-511.
3. File TM. Telithromycin new product overview. *J Allergy Clin Immunol* 2005;115(2):S1-13.
4. Edelstein PH. Pneumococcal resistance to macrolides, lincosamides, ketolides, and streptogramin B agents: molecular mechanisms and resistance phenotypes. *Clin Infect Dis* 2004;38 Suppl 4:S322-7.
5. Wellington K, Noble S. Telithromycin. *Drugs* 2004;64(15):1683-94; discussion 95-6.
6. Personal communication. Susan Swanzy, University of Washington Department of Laboratory Medicine. May 2005.
7. Doern GV, Brown SD. Antimicrobial susceptibility among community-acquired respiratory tract pathogens in the USA: data from PROTEKT US 2000-01. *J Infect* 2004;48(1):56-65.
8. Canton R, Morosini M, Enright MC, et al. Worldwide incidence, molecular epidemiology and mutations implicated in fluoroquinolone-resistant *Streptococcus pneumoniae*: data from the global PROTEKT surveillance programme. *J Antimicrob Chemother* 2003;52(6):944-52.
9. Buchanan PP, Stephens TA, Leroy B. A comparison of the efficacy of telithromycin versus cefuroxime axetil in the treatment of acute bacterial maxillary sinusitis. *Am J Rhinol* 2003;17(6):369-77.
10. Luterman M, Tellier G, Lasko B et al. Efficacy and tolerability of telithromycin for 5 or 10 days vs amoxicillin/clavulanic acid for 10 days in acute maxillary sinusitis. *Ear Nose Throat J* 2003;82(8):576-80, 82-4, 86 passim.
11. Aubier M, Aldons PM, Leak A, et al. Telithromycin is as effective as amoxicillin/clavulanate in acute exacerbations of chronic bronchitis. *Respir Med* 2002;96(11):862-71.
12. Zervos MJ, Heyder AM, Leroy B. Oral telithromycin 800mg once daily for 5 days versus cefuroxime axetil 500mg twice daily for 10 days in adults with acute exacerbations of chronic bronchitis. *J Int Med Res* 2003;31(3):157-69.
13. Ketek (telithromycin) Prescribing Information, Aventis Pharmaceuticals, Sept 2004.
14. Hagberg L, Torres A, van Rensburg D, et al. Efficacy and tolerability of once-daily telithromycin compared with high-dose amoxicillin for treatment of community-acquired pneumonia. *Infection* 2002;30(6):378-86.
15. Tellier G, Niederman MS, Nusrat R, et al. Clinical and bacteriological efficacy and safety of 5 and 7 day regimens of telithromycin once daily compared with a 10 day regimen of clarithromycin twice daily in patients with mild to moderate community-acquired pneumonia. *J Antimicrob Chemother* 2004;54(2):515-23.
16. Pullman J, Champlin J, Vrooman PS. Efficacy and tolerability of once-daily oral

A University of Washington Drug Information Center publication
Distributed monthly by authority of the Pharmacy and Therapeutics Committee
Editor: Nelda A. Murri, Pharm.D. (206) 598-6612 – Asst. Editor: Elizabeth Rudy, D.V.M., R.Ph.
Department of Pharmacy Services / School of Pharmacy

Copyright © 2005 by the University of Washington
Also published on the World Wide Web at <http://uw.prnrx.org/therapyTopics.asp>
No material may be reproduced in whole or in part without written permission from the editor.

Telithromycin, the First FDA-Approved Ketolide (continued)

therapy with telithromycin compared with trovafloxacin for the treatment of community-acquired pneumonia in adults. *Int J Clin Pract* 2003;57(5):377-84.

17. Hagberg L, Carbon C, van Rensburg DJ, et al. Telithromycin in the treatment of community-acquired pneumonia: a pooled analysis. *Respir Med*. 2003 Jun; 97(6):625-33.